Trabeculectomy and MMC a success at nine years

Article

In eyes with primary open angle glaucoma (POAG), trabeculectomy with low dosage mitomycin-C (MMC) and intensified postoperative management offers an increased success rate and a lower incidence of complications, according to Professor Alfredo Reibaldi of the University of Catania, Italy.

In eyes with primary open angle glaucoma (POAG), trabeculectomy with low dosage mitomycin-C (MMC) and intensified postoperative management offers an increased success rate and a lower incidence of complications, according to Professor Alfredo Reibaldi of the University of Catania, Italy.

Patients with POAG, uncontrolled by therapy, who took part in a prospective, randomized, double-blind clinical trial between 1995 and 1999 were reviewed. Subjects originally underwent a trabeculectomy with MMC or saline solution and cases with >9 years follow-up were considered for review.

Of the 133 eyes included in the study, 94 had a >9 years follow-up (57 treated with MMC and 37 with placebo). An IOP of <14 mmHg was found in 47 and 17 eyes, respectively, six and 11 eyes, respectively were taking medical therapy, while four and nine eyes had undergone a re-operation. Glaucomatous visual field progression was noted in five and 16 eyes however, no significant difference was seen in incidence of cataract and other complications.

These nine-year results suggest that trabeculectomy with MMC and intensive postoperative management can significantly improve success rates and decrease the incidence of complications.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.